OPKO Health (NASDAQ:OPK) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

OPKO Health (NASDAQ:OPK) posted its earnings results on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03, Zacks reports. OPKO Health had a negative return on equity of 13.67% and a negative net margin of 28.10%.The firm’s revenue was down 19.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.01 earnings per share.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO completed a second major asset sale of BioReference’s oncology assets and repositioned BioReference as a streamlined, regionally focused clinical lab with a national 4Kscore franchise, which management says positions the diagnostics business for sustained profitable growth in 2026.
• The company struck a collaboration with Regeneron (potentially >$1 billion in milestones plus royalties) and has an EBV vaccine partnership with Merck, providing non-dilutive funding and external development/commercial support for ModeX programs.
• ModeX clinical progress: MDX-2001 has dosed >25 patients with dose escalation showing tolerability and early efficacy signals, MDX-2004 (immune rejuvenator) and MDX-2003 (CD19/CD20 tetraspecific) are in/entering Phase 1, and multiple readouts/phase advances are expected through 2026.
• OPKO entered 2026 with a strong liquidity position (reported $369 million in cash/restricted cash) and an active buyback program (34.6M shares repurchased in 2025; ~$113M remaining authorization), which management is using alongside R&D investments.
• Financial headwinds remain as Q4 revenue declined to $148.5M (from $183.6M) after the divestiture, Q4 net loss was $31.3M, and full-year 2026 guidance implies heavy spending with total costs of $725M–$750M driven by increased R&D investment.

OPKO Health Trading Up 1.7%

Shares of NASDAQ OPK traded up $0.02 during mid-day trading on Thursday, hitting $1.20. The stock had a trading volume of 2,137,750 shares, compared to its average volume of 2,457,783. The business has a 50 day moving average price of $1.27 and a two-hundred day moving average price of $1.36. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70. The firm has a market cap of $921.24 million, a P/E ratio of -4.80 and a beta of 1.47.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Thursday, October 30th. Jefferies Financial Group restated a “hold” rating and issued a $1.60 price objective (down from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. JPMorgan Chase & Co. began coverage on shares of OPKO Health in a research report on Thursday, November 20th. They issued a “neutral” rating on the stock. Finally, Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, OPKO Health presently has a consensus rating of “Hold” and an average price target of $2.28.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in OPKO Health by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after buying an additional 67,973 shares during the period. Millennium Management LLC raised its position in shares of OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of OPKO Health by 150.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after purchasing an additional 3,600,378 shares during the period. AQR Capital Management LLC boosted its position in shares of OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after purchasing an additional 1,324,988 shares in the last quarter. Finally, HRT Financial LP purchased a new stake in OPKO Health in the fourth quarter worth $851,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health News Roundup

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Q4 EPS beat — OPKO reported GAAP EPS of ($0.04) versus consensus around ($0.07), showing better-than-expected per?share results for the quarter. Zacks: Q4 results
• Positive Sentiment: Large collaboration with Regeneron — OPKO’s ModeX platform entered a multispecific-antibody research partnership with Regeneron that includes an upfront payment, program milestones and potential royalties; the total collaboration value can exceed $1B if multiple programs succeed. This materially de-risks upside for investors if programs progress. Press release
• Positive Sentiment: Pipeline progress and partner programs — MDX2003 cleared for Phase 1 in Australia, MDX2004/MDX2001 updates were presented at major conferences, and Merck completed a Phase 1 EBV vaccine trial — all signals of clinical momentum. Earnings call transcript
• Positive Sentiment: Solid liquidity and buyback capacity — OPKO reported ~$369.1M in cash and equivalents and has repurchased ~$87.3M of stock with ~ $112.7M remaining authorization, supporting near-term capital flexibility. Press release
• Neutral Sentiment: Analyst stance — Recent consensus rating is “Hold” with median price targets below some upside scenarios; that keeps expectations tempered. Analyst note
• Negative Sentiment: Revenue decline and asset sales — Consolidated Q4 revenue fell to $148.5M (down ~19% YoY), primarily due to sale of BioReference assets, signaling near-term top-line pressure. Press release
• Negative Sentiment: Guidance below Street — 2026 revenue guidance of $530M–$560M and Q1 revenue guidance of $125M–$140M were issued; the full?year midpoint is below some consensus estimates, which may cap multiple expansion. Quiver / release summary
• Negative Sentiment: Wider losses — OPKO reported a Q4 net loss of $31.3M and larger operating losses versus prior year, reflecting higher R&D spend and transition costs that could pressure near-term earnings. Quiver / release summary

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.